Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Wang, Jialu ^a   Hanada, Kenji ^a   Staus, Dean P ^a   Makara, Michael A ^a   Dahal, Giri Raj ^a   Chen, Qiang ^a   Ahles, Andrea ^b   Engelhardt, Stefan ^b,c   Rockman, Howard A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ARRESTIN; CARVEDILOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT I; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; PROPANOLAMINE DERIVATIVE;

CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE EXPRESSION; LIGAND; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; INTERNALIZATION; INVERSE AGONISM; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DEFICIENCY; DRUG EFFECT; FEMALE; GENE KNOCKDOWN; GENETICS; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; MALE; MAPK SIGNALING; METABOLISM;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETA-ARRESTINS; CARBAZOLES; FEMALE; GENE KNOCKDOWN TECHNIQUES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEK293 CELLS; HUMANS; LIGANDS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; PROPANOLAMINES; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-1;

EID: 85035071890     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01855-z     Document Type: Article

References (51)

1. Lagerstrom, M. C. , Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357 (2008).
2. Ma, P. , Zemmel, R. Value of novelty Nat. Rev. Drug Discov. 1, 571-572 (2002).
3. Overington, J. P., Al-Lazikani, B. , Hopkins, A. L. How many drug targets are there Nat. Rev. Drug Discov. 5, 993-996 (2006).
4. Woo, A. Y. , Xiao, R. P. beta-Adrenergic receptor subtype signaling in heart: From bench to bedside. Acta Pharmacol. Sin. 33, 335-341 (2012).
5. Wettschureck, N. , Offermanns, S. Mammalian G proteins and their cell type specific functions. Physiol. Rev. 85, 1159-1204 (2005).
6. Salazar, N. C., Chen, J. , Rockman, H. A. Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim. Biophys. Acta 1768, 1006-1018 (2007).
7. Rajagopal, S., Rajagopal, K. , Lefkowitz, R. J. Teaching old receptors new tricks: Biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
8. Rockman, H. A., Koch, W. J. , Lefkowitz, R. J. Seven-transmembrane-spanning receptors and heart function. Nature 415, 206-212 (2002).
9. Noma, T., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458 (2007).
10. Kim, I. M., et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestinmediated EGFR transactivation. Proc. Natl Acad. Sci. USA 105, 14555-14560 (2008).
11. Luttrell, L. M., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661 (1999).
12. Shenoy, S. K., et al. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 281, 1261-1273 (2006).
13. Ahn, S., Wei, H., Garrison, T. R. , Lefkowitz, R. J. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by betaarrestins 1 and 2. J. Biol. Chem. 279, 7807-7811 (2004).
14. Mangmool, S., Shukla, A. K. , Rockman, H. A. Beta-arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J. Cell. Biol. 189, 573-587 (2010).
15. Kahsai, A. W., et al. Multiple ligand-specific conformations of the beta2-A drenergic receptor. Nat. Chem. Biol. 7, 692-700 (2011).
16. Manglik, A., et al. Structural insights into the dynamic process of beta2-A drenergic receptor signaling. Cell 161, 1101-1111 (2015).
17. Ye, L., Van Eps, N., Zimmer, M., Ernst, O. P. , Prosser, R. S. Activation of the A2A adenosine G-protein-coupled receptor by conformational selection. Nature 533, 265-268 (2016).
18. Rajagopal, S., et al. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377 (2011).
19. Wisler, J. W., Xiao, K., Thomsen, A. R. , Lefkowitz, R. J. Recent developments in biased agonism. Curr. Opin. Cell Biol. 27, 18-24 (2014).
20. Staus, D. P., et al. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature 535, 448-452 (2016).
21. Wisler, J. W., et al. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc. Natl Acad. Sci. USA 104, 16657-16662 (2007).
22. Sauliere, A., et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat. Chem. Biol. 8, 622-630 (2012).
23. Thomsen, A. R., et al. GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling. Cell 166, 907-919 (2016).
24. Chruscinski, A. J., et al. Targeted disruption of the beta2 adrenergic receptor gene. J. Biol. Chem. 274, 16694-16700 (1999).
25. Rohrer, D. K., et al. Targeted disruption of the mouse beta1-adrenergic receptor gene: Developmental and cardiovascular effects. Proc. Natl Acad. Sci. USA 93, 7375-7380 (1996).
26. Rochais, F., et al. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. 117, 229-235 (2007).
27. Daaka, Y., Luttrell, L. M. , Lefkowitz, R. J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88-91 (1997).
28. Xiao, R. P., Ji, X. , Lakatta, E. G. Functional coupling of the beta 2-A drenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 47, 322-329 (1995).
29. Martin, N. P., Whalen, E. J., Zamah, M. A., Pierce, K. L. , Lefkowitz, R. J. PKAmediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. Cell. Signal. 16, 1397-1403 (2004).
30. Koch, W. J., Inglese, J., Stone, W. C. , Lefkowitz, R. J. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J. Biol. Chem. 268, 8256-8260 (1993).
31. Crespo, P., Cachero, T. G., Xu, N. , Gutkind, J. S. Dual effect of betaadrenergic receptors on mitogen-activated protein kinase. Evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition. J. Biol. Chem. 270, 25259-25265 (1995).
32. Nobles, K. N., et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci. Signal. 4, ra51 (2011).
33. Rapacciuolo, A., et al. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J. Biol. Chem. 278, 35403-35411 (2003).
34. Ritter, S. L. , Hall, R. A. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10, 819-830 (2009).
35. Rasmussen, S. G., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
36. Dohlman, H. G., Thorner, J., Caron, M. G. , Lefkowitz, R. J. Model systems for the study of seven-transmembrane-segment receptors. Annu. Rev. Biochem. 60, 653-688 (1991).
37. van Biesen, T., Luttrell, L. M., Hawes, B. E. , Lefkowitz, R. J. Mitogenic signaling via G protein-coupled receptors. Endocr. Rev. 17, 698-714 (1996).
38. Warne, T., Edwards, P. C., Leslie, A. G. , Tate, C. G. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20, 841-849 (2012).
39. Rosenbaum, D. M., et al. Structure and function of an irreversible agonist-beta (2) adrenoceptor complex. Nature 469, 236-240 (2011).
40. Tilley, D. G., Kim, I. M., Patel, P. A., Violin, J. D. , Rockman, H. A. beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J. Biol. Chem. 284, 20375-20386 (2009).
41. Nuber, S., et al. beta-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature 531, 661-664 (2016).
42. Eichel, K., Jullie, D. , von Zastrow, M. beta-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. Nat. Cell Biol. 18, 303-310 (2016).
43. Oligny-Longpre, G., et al. Engagement of beta-arrestin by transactivated insulinlike growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation. Proc. Natl Acad. Sci. USA 109, E1028-E1037 (2012).
44. Packer, M., et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001).
45. McMurray, J. J. , Pfeffer, M. A. Heart failure. Lancet 365, 1877-1889 (2005).
46. Poole-Wilson, P. A., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362, 7-13 (2003).
47. Ohlstein, E. H., et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc. Natl Acad. Sci. USA 90, 6189-6193 (1993).
48. DeGeorge, B. R. Jr et al. Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 117, 1378-1387 (2008).
49. Naga Prasad, S. V., et al. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J. Cell Biol. 158, 563-575 (2002).
50. Ran, F. A., et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
51. Rohrer, D. K., Chruscinski, A., Schauble, E. H., Bernstein, D. , Kobilka, B. K. Cardiovascular and metabolic alterations in mice lacking both beta1-A nd beta2-adrenergic receptors. J. Biol. Chem. 274, 16701-16708 (1999).